CAR-T therapy in solid tumors

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-04-14 DOI:10.1016/j.ccell.2025.03.019

Bing Du, Juliang Qin, Boxu Lin, Jiqin Zhang, Dali Li, Mingyao Liu

引用次数: 0

Abstract

While chimeric antigen receptor (CAR) T cell therapy has shown great success in hematologic malignancies, the effectiveness in solid tumors has been limited by several factors, including antigenic heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME). In this review, we discuss the advancements made in clinical studies and challenges faced by CAR-T therapy for solid tumors. To enhance CAR-T cell efficacy in solid tumors, we explore strategies such as enhancing T cell persistence and cytotoxicity, targeting multiple antigens, and utilizing innovative allogeneic CAR-T cell manufacturing. Additionally, we highlight the potential benefits of combining CAR-T therapies with immune checkpoint inhibitors and other treatment modalities to overcome TME limitations. We remain optimistic about the future of CAR-T cell therapy in solid tumors, emphasizing the need for continued research to refine therapeutic approaches and address the clinical needs of patients with cancer.

查看原文本刊更多论文

CAR-T疗法在实体瘤中的应用

嵌合抗原受体（CAR）T 细胞疗法在血液系统恶性肿瘤中取得了巨大成功，但在实体瘤中的疗效却受到多种因素的限制，包括抗原异质性和肿瘤微环境（TME）的免疫抑制特性。在这篇综述中，我们将讨论CAR-T疗法在实体瘤临床研究中取得的进展和面临的挑战。为了提高 CAR-T 细胞在实体瘤中的疗效，我们探讨了增强 T 细胞持久性和细胞毒性、靶向多种抗原以及利用创新的异体 CAR-T 细胞制造等策略。此外，我们还强调了将 CAR-T 疗法与免疫检查点抑制剂和其他治疗方式相结合以克服 TME 限制的潜在益处。我们对CAR-T细胞疗法在实体瘤领域的前景保持乐观，并强调需要继续开展研究，完善治疗方法，满足癌症患者的临床需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.